KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Nooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock, Xin Gao, William F Pierce, Mallorie H Fiero, Laleh Amiri-Kordestani, Richard Pazdur, Daniel L Suzman

Clin Cancer Res 32(8) 1383-1388

PMID41678313
PMCIDPMC13127607
DOI10.1158/1078-0432.CCR-25-3609
发表日期2026-02-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

On March 28, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy (RC), for adults with muscle-invasive bladder cancer (MIBC). Substantial evidence of effectiveness was obtained from NIAGARA (NCT03732677), a randomized, phase III, open-label trial in cisplatin-eligible patients with MIBC who had not received prior systemic chemotherapy or immunotherapy. A total of 1,063 patients were randomized (1:1) to receive neoadjuvant durvalumab + gemcitabine and cisplatin prior to RC, followed by adjuvant durvalumab (GC-D), or neoadjuvant gemcitabine and cisplatin (GC) prior to RC, with no subsequent adjuvant treatment. The dual primary endpoints were event-free survival (EFS) and pathologic complete response (pCR), both per blinded independent central review. The key secondary endpoint (α-controlled) was overall survival (OS). GC-D demonstrated a statistically significant improvement in EFS compared with GC at the second interim analysis, with a hazard ratio (HR) of 0.68 [95% confidence interval (CI), 0.56-0.82; P < 0.0001]. The median EFS was not reached (NR) for GC-D and was estimated to be 46.1 months (95% CI, 32.3-NR) for GC. There was no statistically significant difference in the pCR rate between the arms. A statistically significant improvement in OS was observed for GC-D compared with G + C, with an HR of 0.75 (95% CI, 0.59-0.93; two-sided P = 0.0106). The median OS was NR in both arms. Safety seemed consistent with the safety profile demonstrated in prior trials of durvalumab in combination with platinum-based chemotherapy.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1.. Kaplan-Meier Plot of Event-Free Survival in NIAGARA Source: FDA generated D = Durvalumab; G = Gemcitabine; C = Cisplatin Note: Figure adapted from the label; there are no restrictions on its use

KM_Plot

EFS

Figure 1 · Panel KM_Plot

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel KM_Plot 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 2

Figure 2.. Kaplan-Meier Plot of Overall Survival in NIAGARA Source: FDA generated D = Durvalumab; G = Gemcitabine; C = Cisplatin

Overall_Survival

Overall survival

Figure 2 · Panel Overall_Survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_Survival 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果